Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shibo Jiang

Showing results (31-40 of 580) with videos related to

Pageof 58
Sort By:
Biochemical and Biophysical Research Communications|April 18, 2006
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activityYuxian He, Jingjing Li, Shibo Jiang
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 9, 2010
HIV-1 gp41 fusion intermediate: a target for HIV therapeuticsChungen Pan, Shuwen Liu, Shibo Jiang
Clinical and Translational Medicine|June 13, 2022
Renaming the SARS-CoV-2 Omicron sublineages as SARS-CoV-3 is contrary to nomenclature standards based on evolutionary and serological evidenceZhongtian Qi, Jianbo Wu, Shibo Jiang
Stem Cell Reports|March 10, 2021
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease OutbreaksMiao Cao, Xiaojie Su, Shibo Jiang
Expert Opinion on Biological Therapy|September 13, 2016
From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domainYanling Wu, Shibo Jiang, Tianlei Ying
Clinical and Translational Medicine|January 19, 2021
Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeuticsShan Su, Qian Wang, Shibo Jiang
Cell Research|March 24, 2021
Double insult: flu bug enhances SARS-CoV-2 infectivityShan Su, Zezhong Liu, Shibo Jiang
Emerging Microbes & Infections|January 24, 2024
Receptor-binding domain-associated serotypes of SARS-CoV-2Zezhong Liu, Lu Lu, Shibo Jiang
Emerging Microbes & Infections|March 17, 2023
Application of "B+1" heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccinesZezhong Liu, Lu Lu, Shibo Jiang
Trends in Immunology|February 1, 2024
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequencesXinling Wang, Lu Lu, Shibo Jiang
Pageof 58

Showing results (31-40 of 580) with videos related to

Sort By:
Pageof 58
Biochemical and Biophysical Research Communications|April 18, 2006
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activityYuxian He, Jingjing Li, Shibo Jiang
Journal of the Formosan Medical Association = Taiwan Yi Zhi|March 9, 2010
HIV-1 gp41 fusion intermediate: a target for HIV therapeuticsChungen Pan, Shuwen Liu, Shibo Jiang
Clinical and Translational Medicine|June 13, 2022
Renaming the SARS-CoV-2 Omicron sublineages as SARS-CoV-3 is contrary to nomenclature standards based on evolutionary and serological evidenceZhongtian Qi, Jianbo Wu, Shibo Jiang
Stem Cell Reports|March 10, 2021
Broad-Spectrum Anti-coronavirus Vaccines and Therapeutics to Combat the Current COVID-19 Pandemic and Future Coronavirus Disease OutbreaksMiao Cao, Xiaojie Su, Shibo Jiang
Expert Opinion on Biological Therapy|September 13, 2016
From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domainYanling Wu, Shibo Jiang, Tianlei Ying
Clinical and Translational Medicine|January 19, 2021
Facing the challenge of viral mutations in the age of pandemic: Developing highly potent, broad-spectrum, and safe COVID-19 vaccines and therapeuticsShan Su, Qian Wang, Shibo Jiang
Cell Research|March 24, 2021
Double insult: flu bug enhances SARS-CoV-2 infectivityShan Su, Zezhong Liu, Shibo Jiang
Emerging Microbes & Infections|January 24, 2024
Receptor-binding domain-associated serotypes of SARS-CoV-2Zezhong Liu, Lu Lu, Shibo Jiang
Emerging Microbes & Infections|March 17, 2023
Application of "B+1" heterologous boosting strategy for preventing infection of SARS-CoV-2 variants with resistance to broad-spectrum coronavirus vaccinesZezhong Liu, Lu Lu, Shibo Jiang
Trends in Immunology|February 1, 2024
SARS-CoV-2 evolution from the BA.2.86 to JN.1 variants: unexpected consequencesXinling Wang, Lu Lu, Shibo Jiang
Pageof 58